Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Zyclara 3.75% cream 250mg sachets
1307000V0BCAAAB
|
Zyclara | Imiquimod | Skin | 245 |
|
Udrate cream
1302010U0BKAAAE
|
Udrate | Urea | Skin | 238 |
|
Chlorhexidine glucon 2%/Isopropyl alcohol 70% soln 3ml
1311020L0AABVBV
|
Chlorhexidine gluconate (Topical cleanser) | Chlorhexidine gluconate | Skin | 223 |
|
Generic Cocois ointment
1305020V0AAAAAA
|
Coal tar (Scalp) | Cocois | Skin | 216 |
|
Pigmanorm cream
1315000G0BLAAA0
|
Pigmanorm | Depigmenting agents | Skin | 216 |
|
Dovobet gel Applicator
1305020D0BCACAG
|
Dovobet | Calcipotriol | Skin | 206 |
|
Scholl Corn Removal 40% plasters washproof
1307000M0BQAFBS
|
Scholl (Corn & Verruca) | Salicylic acid | Skin | 206 |
|
Permitabs 400mg tablets for cutaneous solution
1311060Q0BBAAAC
|
Permitabs | Potassium permanganate | Skin | 205 |
|
Liquid paraffin 65% bath additive
1302011M0AAAIAI
|
Liquid paraffin | Liquid paraffin | Skin | 201 |
|
Locoid Crelo 0.1% topical emulsion
1304000W0BBAGBD
|
Locoid | Hydrocortisone butyrate | Skin | 198 |
|
Chlorhexidine gluconate 0.1% / Cetrimide 0.5% cream
1310050D0AAADAD
|
Cetrimide (Topical) | Cetrimide | Skin | 197 |
|
Liquid paraffin 65% / Acetylated wool alcohols 5% bath oil
1302011M0AAAGAG
|
Liquid paraffin | Liquid paraffin | Skin | 195 |
|
Cutivate 0.05% cream
1304000S0BBAAAA
|
Cutivate | Fluticasone propionate (Topical) | Skin | 192 |
|
Warticon 0.5% solution
1307000K0BBAAAA
|
Warticon | Podophyllotoxin | Skin | 186 |
|
Odaban 20% spray
1312000C0BDACAW
|
Odaban | Aluminium chloride | Skin | 183 |
|
Daktarin Aktiv 2% cream
1310020N0BBAEAA
|
Daktarin (Miconazole nitrate) | Miconazole nitrate | Skin | 175 |
|
Cuderm moisturising lotion
130201000BBLWA0
|
Proprietary compound emollients | Other emollient preparations | Skin | 172 |
|
Avoca wart and verruca treatment set
1307000Q0BBAFAA
|
Avoca | Silver nitrate | Skin | 169 |
|
Lamisil Once 1% solution
131002030BBAEAD
|
Lamisil (Topical) | Terbinafine hydrochloride | Skin | 169 |
|
Fluocinolone acetonide 0.025% / Clioquinol 3% cream
1304000N0AACACA
|
Fluocinolone acetonide | Fluocinolone acetonide | Skin | 167 |
|
Propylene glycol 40% in Clobetasol 0.05% cream
130400000AABLBL
|
Generic compound preparation BNF 1304000 | Other topical corticosteroid preparations | Skin | 167 |
|
Calmurid cream
1302010U0BCAAAE
|
Calmurid (Topical) | Urea | Skin | 164 |
|
Aveeno Skin Relief moisturising lotion with menthol
130201000BBLLA0
|
Proprietary compound emollients | Other emollient preparations | Skin | 160 |
|
Balmonds Skin Salvation ointment
130201000BBLBA0
|
Proprietary compound emollients | Other emollient preparations | Skin | 160 |
|
Salicylic acid 10% ointment in a base
1307000M0AABVBV
|
Salicylic acid (Warts/Calluses) | Salicylic acid | Skin | 159 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.